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<ABSTRACT> 
Fasting glucose level and the risk of incident cardiovascular disease, 
stroke and all-cause mortality among nondiabetic Koreans 
 
Chanshin Park 
 
Department of Medicine 
The Graduate School, Yonsei University 
(Directed by Professor Duk-Chul Lee) 
 
It is well established that diabetes increases the risk of cardiovascular 
disease and mortality. However, the relationships between mortality and 
both nondiabetic hyperglycemia and low fasting glucose level have been 
less clear. To assess this relationship, a prospective cohort study of 
more than one million Koreans was conducted over 10 years. A total of 
1,213,829 Korean people who had not been diagnosed with specific 
medical conditions were grouped according to their baseline fasting 
serum glucose level. Each of the relationships between fasting glucose 
level and the risk of cardiovascular disease incidence and mortality, 
stroke incidence and mortality, and all-cause mortality exhibited 
J-shaped curves after multivariate adjustment for age, body mass index, 
systolic blood pressure, total cholesterol, ALT, alcohol drinking, smoking 
status and physical activity. There was no evidence of a J-shaped curve 
for ischemic heart disease. The incidence or mortality of ischemic heart 
disease increased from at fasting glucose level above 110 mg/dl, but no 
significant change was shown at the low blood sugar level. In conclusion, 
fasting sugar level below 70 mg/dl increases the risk of cardiovascular 
incidence (HR 1.06, 1.02-1.09) and mortality (HR 1.19, 1.10-1.27), 
thrombotic stroke incidence (HR 1.11, 1.05-1.18) and mortality (HR 1.26, 
1.06-1.49), and all-cause mortality (HR 1.07, 1.04-1.10). Fasting 
glucose level between 100 to 109 mg/dl also increases the risk of 
cardiovascular disease, thrombotic stroke, and all-cause mortality, but 
the risk of 100 to 109 mg/dl is lower than the risk of 110 to 125 mg/dl.  
The HR was higher in women than men especially in ischemic stroke. 
Both low glucose level and impaired fasting glucose should be 
considered as a predictor of cardiovascular risk and more attention 
should be paid to women’s abnormal fasting glucose level than men’s. 
------------------------------------------------------------------------------------------------------- 
Key words: glucose, cardiovascular disease, stroke, cerebral infarction, 
ischemic heart disease, mortality, risk factors
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Chanshin Park 
 
Department of Medicine 
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(Directed by Professor Duk-Chul Lee) 
 
 
I. INTRODUCTION 
1. Impaired fasting glucose and the risk of cardiovascular disease 
and mortality 
In 1997 the American Diabetes Association (ADA) lowered 
diagnostic criteria of fasting plasma glucose (FPG) level for 
diabetes mellitus from 140 mg/dl to 126 mg/dl on the grounds 
that the prevalence and incidence of diabetic retinopathy begin 
to increase at approximately a FPG of 125 mg/dl.1 ADA also 
recommended using a new category of impaired fasting glucose 
(IFG) for fasting plasma glucose level 110 to 125 mg/dl in 1997. 
Then, ADA lowered the criteria for IFG from 110 to 100 mg/dl in 
2003 in an effort to better identify individuals at future diabetes 
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risk and also to improve selection of individuals at risk for 
coronary heart disease.1, 2 
Diabetes mellitus is a well established risk factor of all-cause 
and cardiovascular disease mortality.3 Also, nondiabetic 
hyperglycemia has become increasingly recognized as a risk 
factor for cardiovascular disease.3, 4 However, the roles of 
impaired fasting glucose and impaired glucose tolerance in the 
elevation of cardiovascular disease risk or mortality have not 
been clear.5-8 Several studies showed that impaired glucose 
tolerance (IGT) is a risk factor for cardiovascular disease (CVD) 
mortality.9, 10 The Australian Diabetes, Obesity and Lifestyle 
Study (AusDiab) found known diabetes mellitus and impaired 
fasting glucose (IFG) to be independent predictors for CVD 
mortality after adjustment for age, sex and other traditional 
CVD risk factors, but IGT was not.3 The Atherosclerosis Risk in 
Communities (ARIC) Study showed neither isolated IFG nor 
isolated IGT was associated with a more adverse 
cardiovascular disease risk profile.7 
  
2. Low fasting glucose and the risk of cardiovascular disease and 
mortality 
Additional questions of interest examine 1) what constitutes a 
normal glucose value11 and 2) the safety or danger of having 
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low fasting glucose.12 The large Israeli prospective study 
revealed that higher fasting plasma glucose levels within the 
normoglycemic range (below 100 mg/dl) constitute an 
independent risk factor for type 2 diabetes among young 
men.13 Wei et al. documented a U-shaped relation between 
fasting plasma glucose and mortality.14 Participant of the 
study with low fasting plasma glucose levels had a high risk of 
cardiovascular disease and all-cause mortality.14 The study of 
Taiwanese showed a J-shaped curve of relative risks for 
all-cause mortality by levels of fasting blood glucose on 
subjects with no history of diabetes.15 The DECODE study 
published in 2003 found a J-curved risk of long-term mortality 
with the lowest total mortality in subjects with a FPG 81 to 90 
mg/dl.16 There are also another studies found the J-shaped 
relationship between glucose levels and mortality.12, 17 
  
3. The purpose of this study 
The aim of this study is to evaluate 1) the relationship 
between impaired fasting glucose and CVD and all-cause 
mortality and 2) the relationship between low fasting glucose 
level and CVD and all-cause mortality in the Korean population. 
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II. MATERIALS AND METHODS 
 1. Study participants 
     We used the data from the previously published Korean Cancer 
Prevention Study (KCPS).18, 19 The KCPS is a prospective cohort 
investigation of over one million Koreans who were insured by 
Korean Medical Insurance Corporation, the former National 
Health Insurance Corporation. The cohort included governmental 
employees, public and private school teachers, and their 
dependents. The insured were required to have biennial medical 
examinations. The examination was conducted at designated 
hospitals or clinics nationwide by medical staff in accordance 
with the guideline provided by the Korean Medical Insurance 
Corporation. The exam included height, weight and blood 
pressure measurement, hearing test, visual acuity, chest x-ray, 
urinalysis, CBC and routine blood chemistry after overnight 
fasting. Those examined were also asked to provide their 
medical history and respond to questionnaires inquiring lifestyle. 
The cohort includes 1,329,525 Koreans (846,907 men and 
482,618 women) aged 30 to 95 years. 784,870 (59%) subjects 
were enrolled in 1992 and 367,903 (27.7%) in 1993, 98,417 
(7.4%) in 1994, and 78,335 (5.9%) in 1995. From these 1,329,525 
participants, 27,192 subjects with missing information on 
anthropometric evaluation or with extremely low BMI (less than 
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16.0) or short stature (less than 130 cm) were excluded. Anyone 
who had ever been diagnosed with diabetes, hypertension, stoke, 
cancer, liver disease, respiratory disease, tuberculosis or any 
other specific diseases were also excluded from this study. A 
resultant 1,213,819 healthy Korean people were eligible for this 
study. 
 
2. Data collection 
The follow-up period was up to 10 years. The subjects’ 
in-hospital medical records during this period were analyzed for 
their morbidity and mortality. The principal outcome variables 
were 1) ischemic heart disease (International Classification of 
Diseases, tenth revision, ICD-10 codes, I20 to I25), 2) 
cerebrovascular disease or stroke (ICD 10, I60 to I69), 3) 
cardiovascular disease (CVD) which includes ischemic heart 
disease(I20-I25), cerebrovascular disease (I60-I69), 
hypertensive heart disease (I10-15), other forms of heart 
disease likely related to atherosclerotic CVD (I44-I52), disease 
of arteries (I70-I74), and other sudden death, cause unknown 
(R96), and 4) all-cause mortality. The cerebrovascular disease 
(I60-69) included hemorrhagic stroke (I60-I62) and ischemic 
stroke (I63-I66). For those who had more than one event, we 
used only the first event for this analysis. 
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  These outcomes were ascertained from diagnoses on the 
discharge summaries and from causes of death on death 
certificates. In Korea there are certified medical chart recorders 
who review and abstract the medical chart and assign discharge 
diagnosis in a standardized form using World Health 
Organization codes. The recorders also complete death 
certificates based on the information provided by physicians. 
Computerized search of death certificate data from the National 
Statistical Office in Korea was performed for each enrollee. 
  
3. Statistical Analysis 
    Fasting serum glucose levels were categorized as less than 70, 
70 to 84, 85 to 99, 100 to 109, 110 to 125, 126 to 139, and 140 or 
more mg/dl (<3.88, 3.88-4.66, 4.72-5.5, 5.55-6.05, 6.11-6.94, 
7-7.72, and ≥7.77 mmol/L). We used fasting glucose 85 to 99 
mg/dl group as a reference. We computed hazard ratios (HRs; 
the hazard for incidence and mortality in a specific fasting 
glucose group divided by the corresponding hazard in the 
reference group) using Cox proportional hazards modeling to 
adjust for age and other potential confounding factors such as 
body mass index, systolic blood pressure, total cholesterol, ALT, 
alcohol drinking, smoking status and physical activity. All 
analyses were performed with SAS statistical software, version 
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9.2. 
 
III. RESULTS 
1. General characteristics of the study participants 
Of the total 1,213,829 healthy Koreans enrolled in the study, all 
of whom were over the age of 30, 770,556 were men and 
443,273 were women. Their characteristics are described in 
Table 1. 
 
Table 1. Baseline characteristics of the study population 
 
Characteristic Men (N=770,556) 
Women 
(N=443,273) 
Age (yr) 45.0±11.1 49.4±12.1 
Body mass index 23.2±2.6 23.2±3.1 
Systolic BP(mmHg) 124.5±16.0 121.5±19.1 
Diastolic BP(mmHg) 81.0±11.0 78.2±12.6 
Total cholesterol(mg/dl) 191.1±37.7 194.4±39.3 
AST(IU/L) 26.3±16.6 22.4±10.0 
ALT(IU/L) 25.8±19.9 19.3±12.0 
Alcoholic drinking(%)   
No 23.2 85.7 
Yes 76.8 14.3 
Physical activity(%)   
No 71.5 83.4 
Yes 28.6 16.6 
Hypertension    
No 78.9 80.0 
Yes 21.1 20.0 
Smoking status (%)   
Never smoked 20.8 93.8 
Former smoker 20.1 2.0 
Current smoker 59.1 4.1 
    
They are categorized into 7 groups according to their baseline 
fasting serum glucose level (table 2).  
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Table 2. General characteristics in categories of fasting serum glucose level 
 
Fasting 
glucose 
(mg/dl) 
<70 70- 84 
85- 
99 
100- 
109 
110- 
125 
126- 
139 ≥140 
p for  
trend 
Number of 
subjects 
 
65,287 
(5.4%) 
409,137 
(33.7%) 
480,378 
(39.6%) 
140,735 
(11.6%) 
74,013 
(6.1%) 
14,743 
(1.2%) 
29,536 
(2.4%)  
Age (yr) 
 
 
45.6 
±12.1 
45.2 
±11.5 
46.4 
±11.5 
48.2 
±11.6 
49.8 
±11.5 
53.2 
±11.3 
54.0 
±10.6 0.001 
BMI 
 
 
22.7 
±2.7 
22.9 
±2.7 
23.3 
±2.8 
23.6 
±2.8 
23.9 
±2.9 
24.1 
±3.0 
24.0 
±2.9 0.001 
Systolic BP 
 
 
120.8 
±16.3 
121.1 
±16.3 
123.2 
±16.9 
126.2 
±18.0 
129.0 
±18.8 
131.8 
±19.9 
131.9 
±20.2 <.0001 
Diastolic BP 
 
 
78.3 
±11.3 
78.6 
±11.3 
79.9 
±11.5 
81.7 
±11.9 
83.1 
±12.2 
84.4 
±12.7 
84.3 
±12.6 <.0001 
Cholesterol 
 
 
186.1 
±38.2 
187.9 
±36.5 
192.7 
±37.1 
197.5 
±39.2 
200.9 
±41.8 
203.3 
±44.4 
209.7 
±50.6 <.0001 
AST (IU/L) 
 
 
24.0 
±14.8 
23.7 
±12.6 
24.6 
±13.0 
26.4 
±16.2 
23.4 
±20.0 
30.0 
±26.4 
29.3 
±25.9 0.038 
ALT (IU/L) 
 
 
21.6 
±17.6 
22.0 
±16.5 
23.1 
±16.6 
25.3 
±19.1 
27.3 
±21.5 
29.1 
±23.8 
29.5 
±25.7 <.0001 
Alcoholic 
drinking         
No(%) 50.0 48.7 46.0 41.4 38.0 43.3 44.0 <.0001 
Yes(%) 50.0 51.3 54.0 58.7 62.0 56.7 56.0  
Exercise         
No(%) 78.2 77.1 75.8 74.5 42.5 71.4 69.2 <.0001 
Yes(%) 21.9 22.9 24.2 25.6 27.5 28.6 30.8  
Hypertension         
No(%) 84.0 83.6 80.0 73.8 68.0 61.7 61.4 <.0001 
Yes(%) 16.1 16.5 20.0 26.2 32.0 38.4 38.6  
Smoking 
status          
Never smoked 
 
48.7 49.5 48.0 44.0 40.6 43.5 43.1 <.0001 
Former 
smoker 11.2 12.4 13.8 15.1 16.0 15.1 15.8  
Current 
smoker 40.1 38.1 39.2 41.0 43.4 41.4 41.2  
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Most (78.7%) people’s sugar level was below 100 mg/dl. 
Participants with fasting glucose of 85 to 99 mg/dl were 39.6%. 
214,748 subjects (17.8%) had impaired fasting glucose (IFG) by 
2003 ADA criteria. These criteria increased the number of IFG 
three-fold compared with that (6.1%) of 1997 ADA criteria. 
Table 2 shows that people whose fasting glucose levels are 
higher tend to be older and to have higher body mass index, 
blood pressure, total cholesterol and ALT levels. These groups 
show greater incidence of smoking and drinking. They also 
report to exercise more, which is not easy to understand. We 
believe it may be because they have more features of metabolic 
syndrome, and they realize the need for exercise more than their 
young and slim counterparts. 
  
2. Incidence and mortality of cardiovascular disease 
      Cardiovascular disease (CVD) includes ischemic heart disease, 
hypertensive heart disease, other heart disease probably related 
with atherosclerosis, cerebrovascular disease, and disease of 
arteries. CVD also includes sudden death of unknown cause, 
which is usually of cardiac origin. The CVD incidence and 
mortality increased at low glucose level (CVD mortality for <70 
mg/dl, HR 1.19 with 95% CI 1.10-1.27). The IFG also showed 
increased CVD incidence and mortality. The HR of glucose 100 to 
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109 mg/dl group for cardiovascular mortality was 1.06 with 95% 
CI 1.01 to 1.12, and that of glucose 110 to 125 mg/dl was 1.16 
with 95% CI 1.09 to 1.22. The HR increases as the glucose level 
rises, which results in the J-shaped curve (Fig 1).  
 
Table 3. Incidence and mortality of cardiovascular disease in total cohort 
 
Incidence Mortality Fasting 
Glucose Case HR (95%CI)** Case HR (95%CI)** 
<70 3763 1.06(1.02-1.09) 956 1.19(1.10-1.27) 
70-84 22551 1.01(1.00-1.03) 4833 1.04(1.00-1.08) 
85-99 29170 1.00 6182 1.00 
100-109 10247 1.03(1.01-1.06) 2379 1.06(1.01-1.12) 
110-125 6581 1.12(1.09-1.15) 1594 1.16(1.09-1.22) 
126-139 1752 1.29(1.23-1.36) 485 1.34(1.22-1.48) 
≥140 4728 1.80(1.75-1.86) 1229 1.78(1.67-1.90) 
**Adjusted for age, BMI, SBP, total cholesterol, ALT, alcohol drinks, smoking status, and 
physical activity 
 
 
Fig 1.  Fasting glucose and HR for cardiovascular disease incidence  
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When we analyzed men and women separately, both showed the 
same results except for the CVD incidence rate at low glucose 
level in women was not significantly high (Table 4, 5). In men the 
CVD incidence and mortality showed J-shaped curve. In women 
only CVD mortality showed J-shaped curve. 
 
Table 4. Incidence and mortality of cardiovascular disease (CVD) in men 
 
Incidence Mortality Fasting 
Glucose 
(mg/dl) Case 
Rate per 
100,000 
PY* 
HR (95%CI)** Case 
Rate per 
100,000 
PY* 
HR (95%CI)** 
<70 2330 563 1.06 (1.02-1.11) 610 178 1.15 (1.05-1.26) 
70-84 13560 542 1.01 (0.99-1.03) 3005 165 1.02 (0.97-1.07) 
85-99 17985 553 1.00 3922 162 1.00 
100-109 6726 602 1.04 (1.01-1.06) 1537 178 1.03 (0.97-1.09) 
110-125 4468 667 1.10 (1.07-1.14) 1067 190 1.11 (1.03-1.19) 
126-139 1102 800 1.25 (1.18-1.33) 308 239 1.26 (1.12-1.42) 
≥140 3074 1049 1.72 (1.66-1.79) 820 292 1.72 (1.59-1.85) 
* Age-adjusted rate 
**Adjusted for age, BMI, SBP, total cholesterol, ALT, alcohol drinks, smoking status, and 
physical activity 
 
 
 
Table 5. Incidence and mortality of cardiovascular disease (CVD) in women 
 
Incidence Mortality Fasting 
Glucose 
(mg/dl) Case 
Rate per 
100,000 
PY* 
HR (95%CI)** Case 
Rate per 
100,000 
PY* 
HR (95%CI)** 
<70 1433 522 1.04 (0.98-1.10) 346 169 1.25(1.11-1.40) 
70-84 8991 523 1.02 (0.99-1.05) 1828 155 1.09(1.02-1.16) 
85-99 11185 637 1.00 2260 145 1.00 
100-109 3521 553 1.02 (0.98-1.06) 842 166 1.11(1.02-1.20) 
110-125 2113 645 1.13 (1.08-1.18) 527 180 1.22(1.10-1.34) 
126-139 177 761 1.35 (1.24-1.46) 650 245 1.47(1.26-1.72) 
≥140 409 1077 1.91 (1.81-2.01) 1654 286 1.87(1.68-2.09) 
* Age-adjusted rate 
**Adjusted for age, BMI, SBP, total cholesterol, ALT, alcohol drinks, smoking status, and 
physical activity 
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  3. Incidence rate and mortality from ischemic heart disease 
    Among CVD, ischemic heart disease was analyzed. The risk of 
ischemic heart disease and its mortality went up from fasting 
glucose above 100 mg/dl. However, the ischemic heart disease 
incidence and mortality did not rise at the low fasting glucose 
level (Table 6). 
 
 
Table 6. Incidence and mortality of ischemic heart disease in total cohort 
 
Incidence Mortality Fasting 
glucose 
(mg/dl) Case  HR (95%CI)** Case  HR (95%CI)** 
<70 1280  0.98(0.93-1.04) 206  1.09(0.94-1.27) 
70-84 8212  1.00(0.97-1.03) 1160  1.07(0.99-1.15) 
85-99 10710  1.00 1438  1.00 
100-109 3659  1.02(0.98-1.06) 570  1.11(1.01-1.23) 
110-125 2349  1.11(1.06-1.17) 397  1.28(1.15-1.44) 
126-139 591  1.25(1.15-1.36) 118  1.55(1.28-1.87) 
≥140 1629  1.73(1.64-1.82) 330  2.11(1.87-2.39) 
**Adjusted for age, BMI, SBP, total cholesterol, ALT, alcohol drinks, smoking status, and 
physical activity 
 
 
Fig 2. Fasting glucose level and HR for ischemic heart disease incidence 
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The results from men and women did not show significant 
difference in the incidence and mortality of ischemic heart 
disease (Table 7 and 8). 
 
Table 7. Incidence and mortality of ischemic heart disease in men 
 Incidence Mortality 
Fasting 
serum 
glucose 
Case Rate per 
100,000 
PY* 
HR 
(95%CI)** 
Case Rate per 
100,000 
PY* 
HR 
(95%CI)** 
<70 872 195 1.01 
(0.94-1.09) 
145 38 1.04 
(0.87-1.24) 
70-84 5488 200 1.02 
(0.99-1.06) 
848 40 1.07 
(0.97-1.17) 
85-99 7146 253 1.00 1050 78 1.00 
100-109 2646 219 1.05 
(1.00-1.10) 
424 45 1.10 
(0.98-1.24) 
110-125 1688 239 1.09 
(1.04-1.15) 
300 48 1.25 
(1.09-1.42) 
126-139 394 275 1.21 
(1.09-1.34) 
86 68 1.53 
(1.22-1.91) 
≥140 1080 350 1.57 
(1.47-1.68) 
227 74 1.90 
(1.64-2.20) 
* Age-adjusted rate 
**Adjusted for age, BMI, SBP, total cholesterol, ALT, alcohol drinks, smoking status, and 
physical activity 
 
 
Table 8.Incidence and mortality of ischemic heart disease in women 
 Incidence Mortality 
Fasting 
serum 
glucose 
Case Rate per 
100,000 
PY* 
HR 
(95%CI)** 
Case Rate per 
100,000 
PY* 
HR 
(95%CI)** 
<70 408 134 0.91 
(0.82-1.02) 
61 27 1.24 
(0.94-1.64) 
70-84 2724 143 0.95 
(0.90-1.00) 
312 25 1.09 
(0.94-1.27) 
85-99 3564 152 1.00 388 24 1.00 
100-109 1013 149 0.93 
(0.87-1.00) 
146 29 1.09 
(0.90-1.32) 
110-125 661 198 1.14 
(1.04-1.24) 
97 31 1.29 
(1.03-1.61) 
126-139 197 225 1.30 
(1.13-1.51) 
32 55 1.54 
(1.07-2.21) 
≥140 549 356 2.01 
(1.83-2.20) 
103 69 2.62 
(2.09-3.29) 
* Age-adjusted rate 
**Adjusted for age, BMI, SBP, total cholesterol, ALT, alcohol drinks, smoking status, and 
physical activity 
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4. Cerebrovascular disease 
    Total cerebrovascular disease, hemorrhagic stroke and 
ischemic stroke were analyzed with the same method. Total 
stoke mortality increased at low glucose group (<70 mg/dl) and 
hyperglycemic group (above 100 mg/dl). Stroke incidence 
increased at low glucose group (<70 mg/dl) and at a glucose level 
above 110 mg/dl. The incidence and mortality of ischemic stroke 
increased at low glucose group (<70 mg/dl) and hyperglycemic 
group above 100 mg/dl, showing J-shaped curve. The incidence 
and mortality of hemorrhagic stoke were increased only at 
glucose level above 140 mg/dl (Table 9). Men and Women 
showed differences in mortality of thrombotic stroke. The 
incidence of ischemic stroke increased at glucose below 70 
mg/dl and above 100 mg/dl in men. But the mortality from 
ischemic stroke in men was high only at glucose above 140 mg/dl 
(Table 10). In women the incidence rate and mortality both 
increased at sugar above 100 mg/dl. Also low glucose level 
increased the risk of ischemic stroke mortality in women (Table 
11).  
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Table 9. Incidence and mortality of stroke in total cohort 
 
 Incidence Mortality 
Fasting serum 
glucose 
Case  HR (95%CI)** Case  HR (95%CI)** 
Total Stroke       
<70 1992  1.11(1.06-1.17) 635  1.19(1.09-1.30) 
70-84 11272  1.02(0.99-1.04) 3146  1.03(0.98-1.08) 
85-99 14575  1.00 4064  1.00 
100-109 5225  1.04(1.01-1.07) 1544  1.05(0.99-1.11) 
110-125 3405  1.13(1.09-1.18) 1031  1.13(1.05-1.21) 
126-139 995  1.40(1.31-1.49) 312  1.29(1.15-1.45) 
≥140 2681  1.95(1.87-2.04) 801  1.76(1.63-1.90) 
Hemorrhage 
Stroke 
      
<70 575  1.07(0.98-1.17) 230  1.07(0.93-1.23) 
70-84 3281  0.98(0.94-1.03) 1287  1.02(0.95-1.10) 
85-99 4327  1.00 1657  1.00 
100-109 1418  0.96(0.90-1.02) 558  0.94(0.85-1.03) 
110-125 881  1.00(0.93-1.07) 393  1.07(0.95-1.20) 
126-139 217  1.17(0.95-1.43) 107  1.17(0.95-1.43) 
≥140 419  1.31(1.13-1.51) 228  1.31(1.13-1.51) 
Thrombotic 
Stroke 
      
<70 1249  1.11(1.05-1.18) 154  1.26(1.06-1.49) 
70-84 7060  1.02(0.99-1.06) 727  1.03(0.94-1.14) 
85-99 9170  1.00 952  1.00 
100-109 3426  1.07(1.03-1.12) 441  1.26(1.12-1.42) 
110-125 2340  1.22(1.17-1.28) 271  1.26(1.10-1.44) 
126-139 738  1.59(1.47-1.72) 77  1.36(1.07-1.72) 
≥140 2143  2.41(2.30-2.53) 278  2.61(2.28-3.00) 
**Adjusted for age, BMI, SBP, total cholesterol, ALT, alcohol drinks, smoking status, and 
physical activity 
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Fig 3. Fasting glucose level and HR for stroke incidence 
1.11
1.02 1
1.04
1.13
1.4
1.95
0.6
0.8
1
1.2
1.4
1.6
1.8
2
2.2
<70 70-84 85-99 100-109 110-125 126-139 ≥140
FBS, mg/dl
H
a
z
a
rd
 
ra
ti
o
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 18 - 
Table 10. Incidence and mortality of stroke in men 
  
 Incidence Mortality 
Fasting 
serum 
glucose 
Case Rate per 
100,000 
PY* 
HR 
(95%CI)** 
Case Rate per 
100,000 
PY* 
HR 
(95%CI)** 
Total Stroke       
<70 1195 295 1.09 
(1.03-1.16) 
390 115 1.15 
(1.03-1.28) 
70-84 6604 276 1.00 
(0.97-1.03) 
1869 105 1.00 
(0.94-1.07) 
85-99 8870 283 1.00 2481 104 1.00 
100-109 3351 307 1.03 
(0.99-1.07) 
957 112 1.00 
(0.93-1.08) 
110-125 2302 349 1.12 
(1.07-1.17) 
664 120 1.07 
(0.98-1.17) 
126-139 616 428 1.32 
(1.22-1.44) 
193 143 1.19 
(1.02-1.38) 
≥140 1766 578 1.89 
(1.79-1.99) 
532 188 1.72 
(1.56-1.89) 
Hemorrhage 
Stroke 
      
<70 328 78 1.00 
(0.89-1.13) 
143 37 1.06 
(0.89-1.27) 
70-84 1906 74 0.94 
(0.89-1.00) 
779 35 1.02 
(0.93-1.12) 
85-99 2680 80 1.00 1010 34 1.00 
100-109 933 81 0.95 
(0.88-1.03) 
374 36 0.96 
(0.85-1.08) 
110-125 628 92 1.02 
(0.93-1.11) 
271 42 1.12 
(0.98-1.28) 
126-139 139 102 1.01 
(0.85-1.20) 
67 50 1.08 
(0.83-1.40) 
≥140 293 98 1.04 
(0.82-1.18) 
162 53 1.39 
(1.17-1.64) 
Thrombotic 
Stroke 
      
<70 785 197 1.12 
(1.04-1.21) 
97 28 1.15 
(0.93-1.44) 
70-84 4237 181 1.02 
(0.98-1.06) 
444 27 0.97 
(0.85-1.10) 
85-99 5639 184 1.00 619 28 1.00 
100-109 2207 203 1.06 
(1.01-1.12) 
260 32 1.09 
(0.94-1.26) 
110-125 1572 233 1.19 
(1.13-1.26) 
170 32 1.10 
(0.92-1.61) 
126-139 452 307 1.49 
(1.35-1.64) 
46 33 1.19 
(0.88-1.60) 
≥140 1393 449 2.28 
(2.15-2.43) 
190 66 2.45 
(2.07-2.90) 
* Age-adjusted rate 
**Adjusted for age, BMI, SBP, total cholesterol, ALT, alcohol drinks, smoking status, and 
physical activity 
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Table 11. Incidence and mortality of stroke in women 
 Incidence Mortality 
Fasting 
serum 
glucose 
Case Rate per 
100,000 
PY* 
HR 
(95%CI)** 
Case Rate per 
100,000 
PY* 
HR 
(95%CI)** 
Total Stroke       
<70 797 293 1.14 
(1.06-1.23) 
245 119 1.26 
(1.10-1.44) 
70-84 4668 279 1.05 
(1.01-1.09) 
1277 106 1.08 
(1.00-1.16) 
85-99 5705 270 1.00 1583 99 1.00 
100-109 1874 290 1.05 
(1.00-1.11) 
587 111 1.11 
(1.01-1.22) 
110-125 1103 317 1.13 
(1.06-1.21) 
367 122 1.21 
(1.08-1.36) 
126-139 379 420 1.49 
(1.34-1.65) 
119 151 1.45 
(1.20-1.75) 
≥140 915 559 2.00 
(1.86-2.15) 
269 176 1.80 
(1.57-2.05) 
Hemorrhage 
Stroke 
      
<70 247 85 1.17 
(1.02-1.35) 
87 36 1.09 
(0.97-1.37) 
70-84 1375 77 1.04 
(0.97-1.12) 
508 35 1.02 
(0.91-1.15) 
85-99 1647 76 1.00 647 35 1.00 
100-109 485 76 0.97 
(0.87-1.07) 
184 29 0.89 
(0.75-1.05) 
110-125 253 72 0.93 
(0.81-1.07) 
112 34 0.96 
(0.78-1.18) 
126-139 78 86 1.12 
(0.89-1.40) 
40 50 1.34 
(0.97-1.85) 
≥140 126 76 0.98 
(0.82-1.18) 
66 43 1.16 
(0.89-1.50) 
Thrombotic 
Stroke 
      
<70 464 176 1.09 
(0.99-1.21) 
57 28 1.44 
(1.08-1.91) 
70-84 2823 172 1.04 
(0.99-1.09) 
283 25 1.16 
(0.99-1.36) 
85-99 3531 169 1.00 333 22 1.00 
100-109 1219 183 1.08 
(1.01-1.16) 
181 34 1.58 
(1.31-1.89) 
110-125 768 220 1.24 
(1.14-1.34) 
101 34 1.55 
(1.23-1.94) 
126-139 286 314 1.73 
(1.53-1.95) 
31 44 1.63 
(1.11-2.38) 
≥140 750 446 2.55 
(2.35-2.77) 
88 55 2.77 
(2.17-3.52) 
* Age-adjusted rate 
**Adjusted for age, BMI, SBP, total cholesterol, ALT, alcohol drinks, smoking status, and 
physical activity 
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    5. All-cause mortality 
    The relationship between all-cause mortality and fasting 
glucose level also showed J-shaped curve (Table 12). HR 
increased at the low glucose level (<70 mg/dl, HR 1.07, 95% CI 
1.04–1.10) and started to increase from at glucose 100-109 
mg/dl (HR 1.08, 95% CI 1.06-1.11). For the group with glucose 
above 140 mg/dl, HR was 2.07 (95% CI 2.02-2.13). Because 
the low glucose level can be resulted from certain cancer, we 
re-analyzed the previous result, which showed no increase of 
HR at glucose below 90 mg/dl.19 Either glucose below 70 
mg/dl (HR 1.02, 95% CI 0.97-1.07) or glucose 70-84 mg/dl 
(HR 0.99, 95% CI 0.96-1.02) group was not related with 
all-cancer mortality. 
 
Table 12. All-cause mortality in total cohort 
 
 Mortality 
Fasting glucose Case  HR (95%CI)** 
<70 4953  1.07(1.04-1.10) 
70-84 25988  1.00(0.98-1.02) 
85-99 33099  1.00 
100-109 12333  1.08(1.06-1.11) 
110-125 8424  1.24(1.21-1.28) 
126-139 2396  1.43(1.37-1.49) 
≥140 6606  2.07(2.02-2.13) 
**Adjusted for age, BMI, SBP, total cholesterol, ALT, alcohol drinks, smoking status, and 
physical activity 
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Fig 4. Fasting glucose level and HR for all-cause mortality 
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IV. DISCUSSION 
  1. Impaired fasting glucose and CVD incidence and mortality 
According to the findings reported by Nielson et al., nondiabetic 
hyperglycemic (fasting glucose 100 to 125 mg/dl) patients have a 
significantly greater risk for development of coronary artery 
disease.20 The European Diabetes Epidemiology Group examined 
published data to assess the magnitude of the association 
between different thresholds (100 or 110 mg/dl) for IFG and 
diabetes.16 They found that the magnitude of the association 
between diabetes and IFG is greater for IFG defined as fasting 
plasma glucose of 110 to 125 mg/dl (IFG110) than for the new 
category of fasting plasma glucose of 100 to 109 mg/dl 
(IFG100).16 A meta-analysis of 38 prospective studies conducted 
 - 22 - 
by Levitan et al. showed that both fasting glucose level and 
post-challenge blood glucose level were risk markers for CVD 
among apparently healthy individuals without diabetes.4 This 
meta-analysis also showed a linear relationship between CVD 
risk and post-challenge blood glucose level and a possible 
threshold effect with fasting blood glucose level to be around 
100 mg/dl.4 Our findings are also consistent with Levitan’s 
meta-analysis results. The fasting glucose level worked as a risk 
factor after adjusting confounding factors such as age, BMI, BP, 
total cholesterol, ALT, smoking, and physical activity. From 
fasting glucose 100 mg/dl the risk started to increase, although 
the increase of HR in group with fasting glucose 100 to 109 mg/dl 
was smaller than group with fasting glucose above 110 mg/dl.  
Another study with nondiabetic Italian Caucasians showed that 
IFG110 is associated with a worse metabolic and cardiovascular 
risk profile as compared with IFG100.21 IFG110 was associated 
with higher risk of post-challenge glucose intolerance, lower 
levels of circulating IGF-1, and increased levels of inflammatory 
markers including white blood cell count and C-reactive 
protein.21 Andreozzi’s study implies that IFG110 was more 
related with the incidence of diabetes and inflammatory process 
of cardiovascular events than IFG100. In our result, the risk 
increased as the fasting glucose level increased. The change of 
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cutoff value for IFG has been challenged.16, 22 Diagnostic criteria 
are beyond the scope of this study. Instead, we will discuss the 
clinical significance of the fasting glucose level 100 to 110 mg/dl. 
Recently, in the Chinese Multi-provincial Cohort Study23, Liu et 
al. reported that the normal fasting glucose group, impaired 
fasting glucose group and diabetes group with metabolic 
syndrome had increased CVD risk compared to those groups 
without metabolic syndrome. Therefore, Liu et al. concluded that 
the increased CVD risk in individuals with IFG or diabetes was 
largely driven by the coexistence of multiple metabolic disorders 
rather than hyperglycemia per se.23 The Hoorn study also 
suggests high risk of cardiovascular mortality in individuals with 
impaired fasting glucose is explained by conversion to 
diabetes.22 However, glucose is clearly responsible for the 
microvascular complications of diabetes and has a significant 
impact on the pathogenesis of atherosclerotic macrovascular 
disease.24 The Rotterdam Study found IFG 110 to be associated 
with increased arterial stiffness in elderly people without 
diabetes mellitus.25 The CATHAY study found that increased 
levels of glycemia (102 to 124 mg/dl) is adversely associated 
with arterial endothelial dysfunction and intima-media 
thickening.26 With all of the results taken into consideration, 
non-diabetic hyperglycemia, i.e. impaired fasting glucose is an 
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independent risk factor of incident cardiovascular disease, 
ischemic heart disease, stroke and mortality and fasting glucose 
level 110 to 125 mg/dl tends to be more strongly related with the 
risk than fasting glucose level 100 to 109 mg/dl. 
 
2. Low fasting glucose level and cardiovascular risk 
Low fasting plasma glucose level was reported as a predictor of 
cardiovascular disease and all-cause mortality from a 
prospective cohort study of more than 40,000 people by Wei et 
al..14 The lowest total mortality of that study was found in the 
subjects with a FPG in the interval 79 to 109 mg/dl. In the study 
by Balkau et al. the interval of the lowest total mortality was 94 
to 103 mg/dl17 and in the 2003 DECODE study was 81 to 90 
mg/dl.16 The findings by Wändell et al. showed that the lowest 
incidence mortality occurred in the interval of 113 to 121 mg/dl12, 
higher than other studies. In our study, the lowest total mortality 
count occurred within the 85 to 99 mg/dl interval. Although the 
numbers are arbitrary and varied, the trend of J-shaped curve 
with increasing risk at the lower glucose level is consistent.  
 Very low glucose level can be associated with CVD mortality in 
diabetic patients. But the studies mentioned above excluded 
diabetes patients or had very few cases of classic hypoglycemia 
with fasting glucose less than 50 mg/dl. It is not known how the 
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low fasting glucose level can be associated with CVD and 
all-cause mortality in nondiabetic people. Wei et al. hypothesized 
that long-term exposure to low fasting plasma glucose may 
serve as a risk factor of CVD mortality, perhaps through 
abnormal cardiac activity and thrombosis, especially in patients 
with atherosclerosis.14 Tanne et al. reported a J-shaped 
relationship between fasting plasma glucose and incident 
ischemic cerebrovascular events in patients with pre-existing 
atherothrombotic disease.27 Tanne et al. explained that 
hypoglycemia and rapid changes in plasma glucose have been 
shown to increase counter-regulatory hormones such as 
epinephrine and norepinephrine, which may induce 
vasoconstriction, platelet aggregation, and, thereby, ischemia.27, 
28 Further study will be needed to define the association of low 
fasting glucose level and CVD and all-cause mortality. 
Meanwhile, it would be worthwhile to pay more attention to low 
fasting glucose level in addition to nondiabetic hyperglycemia. 
  
3. Sex differences and ischemic stroke 
While elevated fasting glucose was associated with increase 
cardiovascular disease and mortality in both men and women, the 
hazard ratios were higher in women for all endpoints studied. The 
gender difference was particularly marked for ischemic stroke. 
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These findings are consistent with the well established 
interactoion between gender and diabetes (women with diabetes 
have higher increases in cardiovascular risk compared to men 
with diabetes) and with the findings of the DECODE study, which 
showed a significant sex difference for cardiovascular mortality. 
Since women’s nondiabetic hyperglycemia carries higher 
mortality risk then men’s, probably a more aggressive 
intervention should be given to women’s abnormal fasting glucose 
level. 
 
4. Limitations of this study 
   This study did not factor in the conversion to diabetes during 
follow-up and could not define the association between IFG and 
the risk of mortality as independent of the conversion to diabetes 
during follow-up. This study also did not include other 
parameters for metabolic syndrome such as triglyceride, 
HDL-cholesterol, and waist circumference and thus could not 
completely rule out the confounding effect of metabolic 
syndrome. 
   The outcomes were obtained from admission records and death 
certificates. Since their outpatient records were not included, the 
incidence of morbidity would be lower than actual incidence. For 
example, transient ischemic attack or mild angina that was 
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evaluated and treated in outpatient department would have been 
missed. 
The cardiovascular disease in other studies usually accounted for  
all diseases of the circulatory system (ICD-10, I00 to I99) and 
sudden death of unknown origin, but the cardiovascular disease 
in our study did not include some of the diseases of the 
circulatory system (I00-I09, I26-I52, I77-79, I80-99). This also 
could have lowered the incidence and mortality of cardiovascular 
disease. 
 
V. CONCLUSION 
   A prospective cohort of more than one million Korean people for 
over the period of 10 years revealed that fasting glucose level is 
closely related with CVD incidence and mortality and all-cause 
mortality. The J-shaped curve was exhibited for each relationship, 
with the exception of the relationship between ischemic heart 
disease and fasting glucose level. The risk is high when fasting 
glucose level is below 70 mg/dl. The risk also starts to increase 
from a fasting glucose of 100 mg/dl. The increased risk for the 
fasting glucose interval of 100 to 109 mg/dl is smaller than that of 
110 to 125 mg/dl. Both low glucose level and impaired fasting 
glucose should be considered as a predictor of cardiovascular 
disease risk.  
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< ABSTRACT (IN KOREAN)> 
한국인의 공복혈당과 심혈관계질환 및 전체사망률의 관계 
 
<지도교수 이덕철> 
 
연세대학교 대학원 의학과 
 
박찬신 
 
 
당뇨가 심혈관계질환의 발생 및 사망률을 높이는 것은 잘 알려진 사실이다. 
그러나 저혈당 및 공복혈당장애와 심혈관계질환의 발병 및 사망률의 
관계는 명확하게 밝혀져 있지 않다. 따라서 이러한 관계를 조사하기 
위하여 백만여 명의 한국인을 대상으로한 코호트 연구가 십 년 동안 
행하여졌다. 특이한 병력이 없는 1,213,829 명의 한국인이 초기 공복혈당을 
중심으로 분류되었다. 공복혈당과 심혈관계질환의 발병 및 사망률, 
뇌졸중의 발병 및 사망률, 그리고 전체사망률이 모두 J 형 곡선의 관계를 
나타내었다. 허혈성 심질환은 J 형 곡선을 나타내지 않았다. 
허혈성심질환의 경우 공복혈당이 110 mg/dl 이상인 경우 발병율 및 
사망률이 모두 증가하였으나 저혈당에서는 특별한 변화를 보이지 않았다. 
결론적으로 공복혈당이 70 mg/dl 이하인 경우 심혈관계질환의 발병율 (HR 
1.06, 1.02-1.09) 및 사망률 (HR 1.19, 1.10-1.27), 뇌졸중의 발병율 (HR 1.11, 
1.06-1.17) 및 사망률 (HR 1.19, 1.09-1.30), 그리고 전체 사망률 (HR 1.07, 
1.04-1.10)의 증가를 보였다. 공복혈당이 100-109 mg/dl 인 경우에도 
심혈관계질환, 뇌졸중 및 전체 사망률이 증가하나 증가하는 위험도는 
공복혈당 110-125 mg/dl 인 경우에 비하여 미약하였다. 공복혈당의 증가에 
따른 심혈관계의 위험도의 상승은 남성에서보다 여성에서 더 현저하였으며 
특히 허혈성 뇌졸중의 경우 여성에서 위험도의 증가가 높았다. 따라서 
저혈당과 공복혈당장애 모두 심혈관계질환의 위험 요인으로 고려되어야 
하며 여성의 비정상 공복혈당의 경우, 보다 적극적인 개입이 필요하다. 
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